Transoral incisionless fundoplication is not associated with higher rates of post-surgical gastroparesis compared to anti-reflux surgery for GERD
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doaf087 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Fouad Jaber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, Hepatology & Nutrition, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Gastroparesis, Fundoplication, Gastroesophageal Reflux, Postoperative Complications. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Introduction: Transoral incisionless fundoplication (TIF) is a minimally invasive endoscopic procedure used for the management of gastroesophageal reflux disease (GERD) in patients with a hiatal hernia <>2 cm. Because TIF involves transmural fasteners placed across the gastroesophageal junction, there is a theoretical risk of vagal nerve injury leading to gastroparesis. Whether this risk differs from that seen with traditional anti-reflux surgery (ARS) remains unclear. Using the TriNetX multi-institutional database, we conducted a retrospective cohort study of adult patients with GERD who underwent either TIF or ARS. Patients with a prior history of gastroparesis or prior use of prokinetic agents were excluded. The primary outcome was the incidence of new-onset gastroparesis within 1 month to 1 year after the procedure; secondary outcome was the use of prokinetic agents. Propensity score matching was applied to balance baseline characteristics, including age, sex, race, BMI, diabetes, PPI, and opioid use. A total of 668 TIF and 53,996 ARS patients were identified. Before matching, gastroparesis incidence was similar between TIF (1.48%) and ARS (1.46%) (adjusted odds ratio [aOR] 1.01, 95% CI 0.54–1.9). After matching, the incidence remained comparable between TIF (0.7%) and ARS (1%) (aOR 1.0, 95% CI 0.22–2.26). The 1-year incidence of prokinetic agent use was lower in the TIF group (3.2%) than in the ARS group (6%) (aOR 0.51, 95% CI 0.3–0.9). In summary, post-surgical gastroparesis is rare after both TIF and ARS, with no significant difference between the two procedures. However, the need for prokinetic therapy was lower following TIF, suggesting a potentially lower burden of postoperative gastric motility symptoms. These findings may help guide counseling and individualized decision-making in GERD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Gastroenterology, Hepatology & Nutrition, Baylor College of Medicine, Houston, TX, USA.
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
- Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Faculty of Medicine, Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan.
- Section of Endoluminal Surgery and Interventional Gastroenterology, McGovern Medical School at UTHealth Houston, Houston, TX, USA.
ORCID-Profile: Wasseem Skef
Zitieren
APA
Jaber, F., Gioe, B., Obiedat, K., Jaber, M., Skef, W., Abidi, W., Patel, K., & Ayoub, F. (2025). Transoral incisionless fundoplication is not associated with higher rates of post-surgical gastroparesis compared to anti-reflux surgery for GERD. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf087
Vancouver
Jaber F, Gioe B, Obiedat K, Jaber M, Skef W, Abidi W, et al. Transoral incisionless fundoplication is not associated with higher rates of post-surgical gastroparesis compared to anti-reflux surgery for GERD. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf087
BibTeX
@article{Jaber2025,
author = {Jaber, Fouad and Gioe, Brennan and Obiedat, Kinan and Jaber, Mohamed and Skef, Wasseem and Abidi, Wasif and Patel, Kalpesh and Ayoub, Fares},
title = {Transoral incisionless fundoplication is not associated with higher rates of post-surgical gastroparesis compared to anti-reflux surgery for GERD},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doaf087}
}
EUVIMED